CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)

MLA

L. Paz-Ares Rodriguez, et al. “CANOPY-2: A Phase III, Placebo-Controlled Study of Canakinumab with or without Docetaxel in Patients (Pts) with NSCLC Previously Treated with PD-(L)1 Inhibitors and Platinum-Based Chemotherapy (Ctx).” Annals of Oncology, vol. 30, Nov. 2019, pp. ix179-ix180. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6864d2df2ee29a6096f3cdd4e38a81d5&authtype=sso&custid=ns315887.

APA

L. Paz-Ares Rodriguez, J. H. Kang, Yasushi Goto, Vassiliki A. Papadimitrakopoulou, J.C.-H. Yang, Hiroyasu Kaneda, D. Lim, Bijoyesh Mookerjee, C.-H. Chiu, I. Malet, Martin Reck, Kenneth J. O’Byrne, Z. Zewen, Sang We Kim, W. Su, & Byoung Chul Cho. (2019). CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx). Annals of Oncology, 30, ix179-ix180.

Chicago

L. Paz-Ares Rodriguez, J. H. Kang, Yasushi Goto, Vassiliki A. Papadimitrakopoulou, J.C.-H. Yang, Hiroyasu Kaneda, D. Lim, et al. 2019. “CANOPY-2: A Phase III, Placebo-Controlled Study of Canakinumab with or without Docetaxel in Patients (Pts) with NSCLC Previously Treated with PD-(L)1 Inhibitors and Platinum-Based Chemotherapy (Ctx).” Annals of Oncology 30 (November): ix179-ix180. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6864d2df2ee29a6096f3cdd4e38a81d5&authtype=sso&custid=ns315887.